ClinicalTrials.gg
CompletedNCT06663436Updated Oct 26, 2026Results posted

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

A Phase 2 interventional study of altSonflex1-2-3 Dose A and altSonflex1-2-3 Dose B in Diarrhoea, sponsored by GlaxoSmithKline. Completed at 1 site in Kenya. Open to participants aged 39 Weeks to 43 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Updated Oct 26, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
39 Weeks to 43 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Diarrhea with a site in Kenya — 3 open to participants now, 6 under way, 1 of them phase 3. Diarrhea · Kenya.

Enrollment
18th of 21
200 · median 600
Started
2024
the only one that year
Phase 2
2 of 25
1 open now
Registered
24th of 25
by date
Lead sponsor
3 of 25
GlaxoSmithKline

Among the 25 studies in Diarrhea with a site in Kenya, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 24th registered.

Diarrhea

878 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

3 of the 25 studies in Diarrhea with a site in Kenya are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Kenya have not opened yet or have stopped. Only those recruiting at a site in Kenya →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 39 Weeks to 43 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diarrhea with a site in Kenya, or all of them as a file.
02

Study summary

This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants. The candidate vaccine, altSonflex1-2-3, is currently being evaluated in a Phase 2 age de-escalation (from least vulnerable adult population to most vulnerable paediatric population) clinical study in Kenya, with the aim of identifying a preferred dose, using a 3-dose vaccination schedule in infants from 9 months of age (NCT05073003). This Phase 2 clinical study will evaluate the safety and immunogenicity of an alternative 2-dose vaccination schedule.

03

Conditions studied

  • Diarrhoea

Keywords

  • Shigella
  • Shigellosis
  • altSonflex1-2-3
  • Infants
  • African
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
39 Weeks to 43 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants' parent(s)/ Legally acceptable representative (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
  • Healthy participants as established by medical history, clinical examination, and laboratory assessment.
  • Participants satisfying all screening requirements.
  • Participants seronegative for , and .
  • A male or female 9 months of age at the time of the first study intervention administration.
  • Normal nutritional z-score.
  • Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s).
  • Born at a gestation period of >=37 weeks to the best knowledge of the participant's parent(s)/LAR(s).
  • Participants negative for as confirmed by DNA polymerase chain reaction testing.
  • Participants negative for HLA-B27.

Exclusion criteria

Exclusion Criteria:

  • Known exposure to Shigella during lifetime of the participant as confirmed during interview with the participant's parent(s)/LAR(s) or documented by participant's records.
  • Progressive, unstable, or uncontrolled clinical conditions.
  • History (known or suspected) of any reaction or likely to be exacerbated by any component of the study intervention.
  • Major congenital defects, as assessed by the investigator.
  • Recurrent history or uncontrolled neurological disorders or seizures.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination.
  • Hypersensitivity (known or suspected), including allergy, to medicinal products, vaccines, or medical equipment whose use is foreseen in this study.
  • Clinical conditions representing a to intramuscular vaccination and blood draws.
  • Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
  • Acute disease and/or fever (defined as temperature >=38.0°C) at the time of enrollment.
  • Any hematological and/or biochemical laboratory abnormality.
  • Confirmed positive COVID-19 test during the period starting 30 days before the first administration of study interventions (Day -30 to Day 1).
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -30 to Day 1), or their planned use during the study period.
  • Planned administration/administration of a vaccine/product not foreseen by the Protocol in the period starting 21 days before the first dose and ending after the last dose of study intervention(s) administration with the exception of Coronavirus disease 2019 (COVID-19) vaccines and Expanded Program on Immunization (EPI) vaccines.
  • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Prior receipt of an experimental Shigella vaccine or live Shigella challenge.
  • Prior receipt of a Typhoid conjugate vaccine (TCV).
  • Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, from birth or planned administration during the study period.
  • Chronic administration of immune-modifying drugs (defined as more than 14 days consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention drug or invasive medical device.
  • Any study personnel or immediate dependents, family, or household member.
  • Child in care.
  • Participants who do not meet eligibility criteria for administration of control vaccines.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    altSonflex1-2-3 Low Dose Group

    Participants received 2 low doses of altSonflex1-2-3 and 2 doses of the measles and rubella vaccine (MR-VAC) one each on Day 1 and Day 169.

    Biological: altSonflex1-2-3 Dose A · Biological: MR-VAC

  • Experimental
    altSonflex1-2-3 Medium Dose Group

    Participants received 2 medium doses of altSonflex1-2-3 and 2 doses of MR-VAC one each on Day 1 and Day 169.

    Biological: altSonflex1-2-3 Dose B · Biological: MR-VAC

  • Experimental
    altSonflex1-2-3 High Dose Group

    Participants received 2 high doses of altSonflex1-2-3 and 2 doses of MR-VAC one each on Day 1 and Day 169.

    Biological: altSonflex1-2-3 Dose C · Biological: MR-VAC

  • Active comparator
    Control Group

    Participants received 1 dose of the TYPHIBEV vaccine on Day 1 and 1 dose of the Infanrix Hexa vaccine on Day 169, along with 2 doses of MR-VAC on Day 1 and Day 169.

    Biological: TYPHIBEV · Combination Product: Infanrix hexa · Biological: MR-VAC

Interventions

  • BiologicalaltSonflex1-2-3 Dose A

    altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169

    Also known as: Shigella vaccine

  • BiologicalaltSonflex1-2-3 Dose B

    altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169

    Also known as: Shigella vaccine

  • BiologicalaltSonflex1-2-3 Dose C

    altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169

    Also known as: Shigella vaccine

  • BiologicalTYPHIBEV

    TYPHIBEV administered intramuscularly on Day 1

    Also known as: Biological E. Limited's Typhoid Vi-CRM197 conjugate vaccine

  • Combination productInfanrix hexa

    Infanrix hexa administered intramuscularly on Day 169

    Also known as: GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated) and Haemophilus influenzae type b vaccine (adsorbed)

  • BiologicalMR-VAC

    MR-VAC co-administered subcutaneously on Day 1 and Day 169

    Also known as: Serum Institute of India's Measles and rubella vaccine (live)

06

What researchers measure

Primary outcomes

  1. Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)

    Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

    Time frame: At Day 1 (before administration of Dose 1)

  2. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG

    Time frame: At Day 29 (28 days after administration of Dose 1)

  3. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG

    Time frame: At Day 169 (before administration of Dose 2)

  4. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG

    Time frame: At Day 197 (28 days after administration of Dose 2)

  5. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG

    S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

    Time frame: At Day 29 compared to baseline (before administration of Dose 1 on Day 1)

  6. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG

    Time frame: At Day 197 compared to baseline (before administration of Dose 1 on Day 1)

  7. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG

    Time frame: At Day 197 compared to pre-Dose 2 at Day 169

Secondary outcomes

  1. Number of Participants With Solicited Administration Site Events

    The solicited administration site events assessed were erythema, pain and swelling.

    Time frame: During the 7 days after each study intervention administration (study intervention administered at Day 1 and Day 169)

  2. Number of Participants With Solicited Systemic Events

    The solicited systemic event assessed was fever (pyrexia). Fever is defined as temperature ≥38.0°Celsius (C), measured axillary.

    Time frame: During the 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169)

  3. Number of Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

    Time frame: During the 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169)

  4. Number of Participants With Serious AEs (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: Day 1 to Day 197

  5. Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: Day 8 compared to baseline (pre-Dose 1 at Day 1)

  6. Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 176

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 169 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: Day 176 compared to pre-Dose 2 at Day 169

  7. The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade Values

    Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.

    Time frame: Day 8 compared to baseline (before administration of Dose 1 at Day 1)

  8. The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade Values

    Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 169 and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.

    Time frame: Day 176 compared to pre-Dose 2 at Day 169

  9. Anti-measles IgG Concentrations Expressed as GMCs

    Anti-measles IgG concentrations were expressed as GMCs in EU/mL.

    Time frame: At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)

  10. Anti-rubella IgG Concentrations Expressed as GMCs

    Anti-rubella IgG concentrations were expressed as GMCs in EU/mL.

    Time frame: At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)

  11. Number of Participants Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL

    Time frame: At Day 197 (28 days after the second MR-VAC vaccination)

  12. Number of Participants Achieving Anti-rubella IgG Concentrations of ≥4 IU/mL and ≥10 IU/mL

    Time frame: At Day 197 (28 days after the second MR-VAC vaccination)

07

Results

Posted Oct 26, 2026

Participant flow

Participant flow — Overall Study
MilestonealtSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Started50505050
Completed47424848
Not completed3822
Withdrew: Lost to follow-up2200
Withdrew: Withdrawal by subject1522
Withdrew: Other0100

Outcome measures

PrimaryGeometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)

Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

Time frame:
At Day 1 (before administration of Dose 1)
Reported as:
Geometric mean · ELISA units per milliliter (EU/mL)
Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)
ELISA units per milliliter (EU/mL)altSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei7.4 (6.5 to 8.3)8.1 (7.0 to 9.5)8.7 (6.6 to 11.5)9.2 (7.3 to 11.7)
S. flexneri 1b5.5 (4.4 to 6.9)8.3 (5.7 to 12.1)7.6 (5.6 to 10.4)6.1 (4.7 to 7.9)
S. flexneri 2a5.1 (3.8 to 6.9)4.9 (3.4 to 7.1)4.6 (3.1 to 6.8)4.0 (2.9 to 5.6)
S. flexneri 3a3.9 (2.9 to 5.2)5.1 (3.4 to 7.6)4.2 (3.0 to 6.0)4.2 (3.0 to 5.7)
PrimaryGMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame:
At Day 29 (28 days after administration of Dose 1)
Reported as:
Geometric mean · EU/mL
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
EU/mLaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei44.6 (32.2 to 61.7)66.4 (46.9 to 93.9)59.5 (44.7 to 79.1)8.7 (7.0 to 10.8)
S. flexneri 1b20.2 (13.9 to 29.5)48.7 (35.1 to 67.7)30.5 (20.4 to 45.6)6.5 (4.8 to 8.9)
S. flexneri 2a71.3 (43.1 to 117.8)98.4 (64.0 to 151.3)77.1 (53.8 to 110.5)4.5 (3.1 to 6.7)
S. flexneri 3a11.0 (7.1 to 16.9)24.1 (15.4 to 37.9)16.6 (11.2 to 24.6)5.2 (3.5 to 7.6)
PrimaryGMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame:
At Day 169 (before administration of Dose 2)
Reported as:
Geometric mean · EU/mL
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
EU/mLaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei26.0 (16.4 to 41.3)34.7 (22.9 to 52.6)33.5 (23.3 to 48.3)10.6 (7.1 to 15.8)
S. flexneri 1b12.0 (8.3 to 17.2)16.2 (11.2 to 23.4)14.4 (10.0 to 20.9)13.2 (9.0 to 19.3)
S. flexneri 2a11.2 (7.2 to 17.5)13.4 (8.8 to 20.6)9.6 (6.2 to 14.8)6.0 (4.0 to 8.9)
S. flexneri 3a6.0 (4.0 to 9.0)10.1 (6.8 to 14.9)8.0 (5.4 to 12.0)8.4 (5.5 to 12.7)
PrimaryGMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame:
At Day 197 (28 days after administration of Dose 2)
Reported as:
Geometric mean · EU/mL
GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgG
EU/mLaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei802.1 (521.4 to 1234.0)1320.3 (903.8 to 1928.8)1080.7 (675.7 to 1728.5)10.6 (7.2 to 15.6)
S. flexneri 1b32.0 (23.9 to 42.9)39.8 (28.3 to 55.9)32.3 (22.5 to 46.3)12.4 (8.5 to 18.3)
S. flexneri 2a83.5 (58.0 to 120.1)92.8 (63.7 to 135.1)75.3 (52.3 to 108.4)5.1 (3.5 to 7.3)
S. flexneri 3a19.8 (13.4 to 29.2)31.9 (23.0 to 44.3)19.1 (12.4 to 29.5)7.9 (5.1 to 12.1)
PrimaryNumber of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG

S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

Time frame:
At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei3231350
S. flexneri 1b2130273
S. flexneri 2a3738393
S. flexneri 3a1923224
PrimaryNumber of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame:
At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei4242435
S. flexneri 1b28222211
S. flexneri 2a4037378
S. flexneri 3a22242712
PrimaryNumber of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
Time frame:
At Day 197 compared to pre-Dose 2 at Day 169
Reported as:
Count of participants · Participants
Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
S. sonnei3639410
S. flexneri 1b13881
S. flexneri 2a3130290
S. flexneri 3a161573
SecondaryNumber of Participants With Solicited Administration Site Events

The solicited administration site events assessed were erythema, pain and swelling.

Time frame:
During the 7 days after each study intervention administration (study intervention administered at Day 1 and Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Administration Site Events
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Erythema, post-Dose 17663
Erythema, post-Dose 23374
Pain, post-Dose 11114173
Pain, post-Dose 211131113
Swelling, post-Dose 179122
Swelling, post-Dose 271076
SecondaryNumber of Participants With Solicited Systemic Events

The solicited systemic event assessed was fever (pyrexia). Fever is defined as temperature ≥38.0°Celsius (C), measured axillary.

Time frame:
During the 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Events
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Fever, post-Dose 110697
Fever, post-Dose 241056
SecondaryNumber of Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

Time frame:
During the 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Unsolicited AEs, post-study intervention administered at Day 123232424
Unsolicited AEs, post-study intervention administered at Day 1699141217
SecondaryNumber of Participants With Serious AEs (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
Day 1 to Day 197
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs (SAEs)
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Number of Participants With Serious AEs (SAEs)1000
SecondaryNumber of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
Day 8 compared to baseline (pre-Dose 1 at Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
ALT, Below, Below0010
ALT, Below, Within0000
ALT, Below, Above0000
ALT, Within, Below0100
ALT, Within, Within48434747
ALT, Within, Above1111
ALT, Above, Below0000
ALT, Above, Within0111
ALT, Above, Above0000
AST, Below, Below0000
AST, Below, Within0000
AST, Below, Above0000
AST, Within, Below0000
AST, Within, Within48455048
AST, Within, Above0001
AST, Above, Below0000
AST, Above, Within0100
AST, Above, Above1000
Creatinine, Below, Below49465049
Creatinine, Below, Within0000
Creatinine, Below, Above0000
Creatinine, Within, Below0000
Creatinine, Within, Within0000
Creatinine, Within, Above0000
Creatinine, Above, Below0000
Creatinine, Above, Within0000
Creatinine, Above, Above0000
Potassium, Below, Below0000
Potassium, Below, Within0000
Potassium, Below, Above0000
Potassium, Within, Below1000
Potassium, Within, Within48465049
Potassium, Within, Above0000
Potassium, Above, Below0000
Potassium, Above, Within0000
Potassium, Above, Above0000
Sodium, Below, Below0000
Sodium, Below, Within1100
Sodium, Below, Above0000
Sodium, Within, Below0100
Sodium, Within, Within31353735
Sodium, Within, Above10676
Sodium, Above, Below0000
Sodium, Above, Within4365
Sodium, Above, Above3003
Urea, Below, Below23292024
Urea, Below, Within11177
Urea, Below, Above0000
Urea, Within, Below661010
Urea, Within, Within99138
Urea, Within, Above0100
Urea, Above, Below0000
Urea, Above, Within0000
Urea, Above, Above0000
Basophils, Below, Below0000
Basophils, Below, Within0000
Basophils, Below, Above0000
Basophils, Within, Below0000
Basophils, Within, Within27283332
Basophils, Within, Above3644
Basophils, Above, Below0000
Basophils, Above, Within11898
Basophils, Above, Above8445
Eosinophils, Below, Below0000
Eosinophils, Below, Within1010
Eosinophils, Below, Above0000
Eosinophils, Within, Below2300
Eosinophils, Within, Within40404845
Eosinophils, Within, Above2102
Eosinophils, Above, Below0000
Eosinophils, Above, Within3001
Eosinophils, Above, Above1211
Erythrocytes, Below, Below0000
Erythrocytes, Below, Within0000
Erythrocytes, Below, Above0000
Erythrocytes, Within, Below1101
Erythrocytes, Within, Within25282829
Erythrocytes, Within, Above7343
Erythrocytes, Above, Below0000
Erythrocytes, Above, Within1664
Erythrocytes, Above, Above1581212
Hematocrit, Below, Below0011
Hematocrit, Below, Within2303
Hematocrit, Below, Above0000
Hematocrit, Within, Below1300
Hematocrit, Within, Within38363834
Hematocrit, Within, Above6054
Hematocrit, Above, Below0000
Hematocrit, Above, Within1134
Hematocrit, Above, Above1333
Hemoglobin, Below, Below5342
Hemoglobin, Below, Within1324
Hemoglobin, Below, Above0000
Hemoglobin, Within, Below1411
Hemoglobin, Within, Within40323738
Hemoglobin, Within, Above1122
Hemoglobin, Above, Below0000
Hemoglobin, Above, Within1222
Hemoglobin, Above, Above0120
Leukocytes, Below, Below0031
Leukocytes, Below, Within1232
Leukocytes, Below, Above0000
Leukocytes, Within, Below4112
Leukocytes, Within, Within31303133
Leukocytes, Within, Above3441
Leukocytes, Above, Below0000
Leukocytes, Above, Within5947
Leukocytes, Above, Above5043
Lymphocytes, Below, Below0000
Lymphocytes, Below, Within0000
Lymphocytes, Below, Above0000
Lymphocytes, Within, Below0000
Lymphocytes, Within, Within30302633
Lymphocytes, Within, Above5385
Lymphocytes, Above, Below0000
Lymphocytes, Above, Within6676
Lymphocytes, Above, Above8795
Monocytes, Below, Below0100
Monocytes, Below, Within2304
Monocytes, Below, Above0000
Monocytes, Within, Below1011
Monocytes, Within, Within27293927
Monocytes, Within, Above128611
Monocytes, Above, Below0000
Monocytes, Above, Within2234
Monocytes, Above, Above5312
Neutrophils, Below, Below3327
Neutrophils, Below, Within4623
Neutrophils, Below, Above0000
Neutrophils, Within, Below10186
Neutrophils, Within, Within31333533
Neutrophils, Within, Above1110
Neutrophils, Above, Below0000
Neutrophils, Above, Within0220
Neutrophils, Above, Above0000
Platelets, Below, Below0000
Platelets, Below, Within0010
Platelets, Below, Above0000
Platelets, Within, Below0000
Platelets, Within, Within751024
Platelets, Within, Above9783
Platelets, Above, Below0000
Platelets, Above, Within810211
Platelets, Above, Above25242911
SecondaryNumber of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 176

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, blood urea, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Categories reported when comparing Day 169 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
Day 176 compared to pre-Dose 2 at Day 169
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematological, Renal, and Hepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 176
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
ALT, Below, Below0110
ALT, Below, Within0000
ALT, Below, Above0000
ALT, Within, Below0000
ALT, Within, Within44424446
ALT, Within, Above1001
ALT, Above, Below0000
ALT, Above, Within0001
ALT, Above, Above1011
AST, Below, Below0000
AST, Below, Within0000
AST, Below, Above0000
AST, Within, Below0000
AST, Within, Within43414547
AST, Within, Above0001
AST, Above, Below0000
AST, Above, Within1200
AST, Above, Above2011
Creatinine, Below, Below45434547
Creatinine, Below, Within0011
Creatinine, Below, Above1000
Creatinine, Within, Below0001
Creatinine, Within, Within0000
Creatinine, Within, Above0000
Creatinine, Above, Below0000
Creatinine, Above, Within0000
Creatinine, Above, Above0000
Potassium, Below, Below0000
Potassium, Below, Within0000
Potassium, Below, Above0000
Potassium, Within, Below0000
Potassium, Within, Within1111617
Potassium, Within, Above9101413
Potassium, Above, Below0000
Potassium, Above, Within9662
Potassium, Above, Above17162017
Sodium, Below, Below0000
Sodium, Below, Within0000
Sodium, Below, Above0000
Sodium, Within, Below0000
Sodium, Within, Within37384039
Sodium, Within, Above6322
Sodium, Above, Below0000
Sodium, Above, Within3248
Sodium, Above, Above0000
Urea, Below, Below17171619
Urea, Below, Within114911
Urea, Below, Above0000
Urea, Within, Below74610
Urea, Within, Within1118159
Urea, Within, Above0000
Urea, Above, Below0000
Urea, Above, Within0000
Urea, Above, Above0000
Basophils, Below, Below0000
Basophils, Below, Within0000
Basophils, Below, Above0000
Basophils, Within, Below1000
Basophils, Within, Within39374345
Basophils, Within, Above2212
Basophils, Above, Below0000
Basophils, Above, Within1221
Basophils, Above, Above3201
Eosinophils, Below, Below0000
Eosinophils, Below, Within0101
Eosinophils, Below, Above0000
Eosinophils, Within, Below0200
Eosinophils, Within, Within38294039
Eosinophils, Within, Above2242
Eosinophils, Above, Below0000
Eosinophils, Above, Within2015
Eosinophils, Above, Above4912
Erythrocytes, Below, Below0000
Erythrocytes, Below, Within0000
Erythrocytes, Below, Above0000
Erythrocytes, Within, Below0000
Erythrocytes, Within, Within29312828
Erythrocytes, Within, Above2332
Erythrocytes, Above, Below0000
Erythrocytes, Above, Within3356
Erythrocytes, Above, Above1261013
Hematocrit, Below, Below0011
Hematocrit, Below, Within0121
Hematocrit, Below, Above0000
Hematocrit, Within, Below1111
Hematocrit, Within, Within32363333
Hematocrit, Within, Above4233
Hematocrit, Above, Below0000
Hematocrit, Above, Within2146
Hematocrit, Above, Above7224
Hemoglobin, Below, Below2646
Hemoglobin, Below, Within1121
Hemoglobin, Below, Above0000
Hemoglobin, Within, Below0111
Hemoglobin, Within, Within35313835
Hemoglobin, Within, Above2112
Hemoglobin, Above, Below0000
Hemoglobin, Above, Within4201
Hemoglobin, Above, Above2103
Leukocytes, Below, Below0101
Leukocytes, Below, Within1242
Leukocytes, Below, Above0000
Leukocytes, Within, Below1000
Leukocytes, Within, Within30322840
Leukocytes, Within, Above4363
Leukocytes, Above, Below0000
Leukocytes, Above, Within5231
Leukocytes, Above, Above5352
Lymphocytes, Below, Below0000
Lymphocytes, Below, Within0000
Lymphocytes, Below, Above0000
Lymphocytes, Within, Below0000
Lymphocytes, Within, Within28332535
Lymphocytes, Within, Above7379
Lymphocytes, Above, Below0000
Lymphocytes, Above, Within2242
Lymphocytes, Above, Above95103
Monocytes, Below, Below0000
Monocytes, Below, Within0000
Monocytes, Below, Above0000
Monocytes, Within, Below0000
Monocytes, Within, Within36363842
Monocytes, Within, Above3335
Monocytes, Above, Below0000
Monocytes, Above, Within7142
Monocytes, Above, Above0310
Neutrophils, Below, Below2230
Neutrophils, Below, Within4307
Neutrophils, Below, Above0000
Neutrophils, Within, Below2622
Neutrophils, Within, Within35324038
Neutrophils, Within, Above0001
Neutrophils, Above, Below0000
Neutrophils, Above, Within3011
Neutrophils, Above, Above0000
Platelets, Below, Below0000
Platelets, Below, Within0000
Platelets, Below, Above1110
Platelets, Within, Below0000
Platelets, Within, Within75620
Platelets, Within, Above1061212
Platelets, Above, Below0000
Platelets, Above, Within3433
Platelets, Above, Above25272414
SecondaryThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade Values

Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 1 (baseline) and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.

Time frame:
Day 8 compared to baseline (before administration of Dose 1 at Day 1)
Reported as:
Number · Participants
The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade Values
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
ALT, Grade 0, Grade 049455048
ALT, Grade 0, Grade 10101
AST, Grade 0, Grade 049465049
Creatinine, Grade 0, Grade 049465049
Hemoglobin, Grade 0, Grade 042364342
Hemoglobin, Grade 0, Grade 11411
Hemoglobin, Grade 1, Grade 01324
Hemoglobin, Grade 1, Grade 15242
Hemoglobin, Grade 2, Grade 20100
Neutrophils Decrease, Grade 0, Grade 032363833
Neutrophils Decrease, Grade 0, Grade 18186
Neutrophils Decrease, Grade 1, Grade 01522
Neutrophils Decrease, Grade 1, Grade 11215
Neutrophils Decrease, Grade 1, Grade 20001
Neutrophils Decrease, Grade 1, Grade 30101
Neutrophils Decrease, Grade 1, Grade 41000
Neutrophils Decrease, Grade 2, Grade 02001
Neutrophils Decrease, Grade 2, Grade 11000
Neutrophils Decrease, Grade 3, Grade 01100
Neutrophils Decrease, Grade 3, Grade 10010
Platelets Decrease, Grade 0, Grade 049464949
Platelets Decrease, Grade 1, Grade 00010
WBC Decrease, Grade 0, Grade 044434344
WBC Decrease, Grade 0, Grade 14112
WBC Decrease, Grade 1, Grade 01232
WBC Decrease, Grade 1, Grade 10031
SecondaryThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade Values

Panel tests include measures of ALT, AST, creatinine, hemoglobin, neutrophils decrease, platelets decrease and white blood cells (WBC) decrease. Categories reported when comparing Day 169 and laboratory reference range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<grade at baseline\>,\<grade at timing\>, where Grade 0=within reference range, Grade 1= mild, Grade 2=moderate, Grade 3=severe and Grade 4=potentially life threatening laboratory abnormality.

Time frame:
Day 176 compared to pre-Dose 2 at Day 169
Reported as:
Number · Participants
The Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade Values
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
ALT, Grade 0, Grade 045434548
ALT, Grade 0, Grade 10001
ALT, Grade 1, Grade 01000
ALT, Grade 1, Grade 20010
AST, Grade 0, Grade 045434548
AST, Grade 1, Grade 01001
AST, Grade 1, Grade 10010
Creatinine, Grade 0, Grade 045434648
Creatinine, Grade 0, Grade 21001
Hemoglobin, Grade 0, Grade 043353941
Hemoglobin, Grade 0, Grade 10111
Hemoglobin, Grade 1, Grade 01121
Hemoglobin, Grade 1, Grade 11302
Hemoglobin, Grade 1, Grade 20123
Hemoglobin, Grade 2, Grade 10220
Hemoglobin, Grade 2, Grade 21000
Hemoglobin, Grade 2, Grade 30001
Neutrophils Decrease, Grade 0, Grade 038324141
Neutrophils Decrease, Grade 0, Grade 12621
Neutrophils Decrease, Grade 1, Grade 02207
Neutrophils Decrease, Grade 1, Grade 12030
Neutrophils Decrease, Grade 1, Grade 20000
Neutrophils Decrease, Grade 1, Grade 30000
Neutrophils Decrease, Grade 1, Grade 40000
Neutrophils Decrease, Grade 2, Grade 02000
Neutrophils Decrease, Grade 2, Grade 10000
Neutrophils Decrease, Grade 2, Grade 20100
Neutrophils Decrease, Grade 3, Grade 00100
Neutrophils Decrease, Grade 3, Grade 10100
Platelets Decrease, Grade 0, Grade 045424549
Platelets Decrease, Grade 1, Grade 01110
WBC Decrease, Grade 0, Grade 044404246
WBC Decrease, Grade 0, Grade 11000
WBC Decrease, Grade 1, Grade 01242
WBC Decrease, Grade 1, Grade 10101
SecondaryAnti-measles IgG Concentrations Expressed as GMCs

Anti-measles IgG concentrations were expressed as GMCs in EU/mL.

Time frame:
At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
Reported as:
Geometric mean · EU/mL
Anti-measles IgG Concentrations Expressed as GMCs
EU/mLaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Day 125.4 (24.6 to 26.2)25.0 (25.0 to 25.0)25.5 (24.5 to 26.4)25.8 (24.2 to 27.5)
Day 1971005.0 (855.0 to 1181.3)835.6 (685.7 to 1018.3)923.9 (783.7 to 1089.0)954.1 (836.2 to 1088.6)
SecondaryAnti-rubella IgG Concentrations Expressed as GMCs

Anti-rubella IgG concentrations were expressed as GMCs in EU/mL.

Time frame:
At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
Reported as:
Geometric mean · EU/mL
Anti-rubella IgG Concentrations Expressed as GMCs
EU/mLaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Day 11.0 (1.0 to 1.1)1.1 (1.0 to 1.2)1.2 (1.1 to 1.4)1.1 (1.0 to 1.2)
Day 19791.1 (84.4 to 98.3)78.3 (68.2 to 89.8)85.1 (76.9 to 94.2)84.4 (77.7 to 91.7)
SecondaryNumber of Participants Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
Time frame:
At Day 197 (28 days after the second MR-VAC vaccination)
Reported as:
Count of participants · Participants
Number of Participants Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
>= 150 mIU/mL44414445
>= 200 mIU/mL44414445
SecondaryNumber of Participants Achieving Anti-rubella IgG Concentrations of ≥4 IU/mL and ≥10 IU/mL
Time frame:
At Day 197 (28 days after the second MR-VAC vaccination)
Reported as:
Count of participants · Participants
Number of Participants Achieving Anti-rubella IgG Concentrations of ≥4 IU/mL and ≥10 IU/mL
ParticipantsaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
>= 4 IU/mL44424445
>= 10 IU/mL44414445

Adverse events

Collected over Solicited AEs: within 7 days after any vaccination. Unsolicited AEs: within 28 days after any vaccination. All-cause mortality and SAEs: From Day 1 until Day 197.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
altSonflex1-2-3 Low Dose Group0/50 (0%)1/50 (2%)41/50 (82%)
altSonflex1-2-3 Medium Dose Group0/50 (0%)0/50 (0%)35/50 (70%)
altSonflex1-2-3 High Dose Group0/50 (0%)0/50 (0%)42/50 (84%)
Control Group0/50 (0%)0/50 (0%)40/50 (80%)
Most frequent serious events
Most frequent serious events
EventaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
GastroenteritisInfections and infestations1/500/500/500/50
Most frequent other events
Showing 10 of 46
Most frequent other events
EventaltSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl Group
Administration site painGeneral disorders15/5019/5023/5015/50
Administration site swellingGeneral disorders12/5013/5018/508/50
Upper respiratory tract infectionInfections and infestations8/508/506/5013/50
PyrexiaGeneral disorders12/5012/509/5010/50
RhinitisInfections and infestations5/508/508/5012/50
Administration site erythemaGeneral disorders8/507/5010/507/50
GastroenteritisInfections and infestations4/505/502/506/50
TonsillitisInfections and infestations5/501/504/501/50
AmoebiasisInfections and infestations0/504/503/500/50
DiarrhoeaGastrointestinal disorders3/504/503/503/50

Baseline characteristics

Age, Continuous
Age, Continuous(Months)altSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl GroupTotal
Mean9.3 ± 0.59.3 ± 0.59.3 ± 0.59.3 ± 0.59.3 ± 0.5
Sex: Female, Male
Sex: Female, Male(Participants)altSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl GroupTotal
Female29212735112
Male2129231588
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)altSonflex1-2-3 Low Dose GroupaltSonflex1-2-3 Medium Dose GroupaltSonflex1-2-3 High Dose GroupControl GroupTotal
BLACK OR AFRICAN AMERICAN50505050200
08

Study locations

1 site
  • GSK Investigational Site
    Kericho, 20200, Kenya
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Oct 2025, 11 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 24 industry-sponsored phase 2 interventional studies under Diarrhea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 20. This study's 11 months is below that.

Counting every sponsor, half of 47 studies reached it within 15 months; a quarter within 11 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 29, 2024
StartActual
Nov 13, 2024
Primary completionActual
Oct 21, 2025
CompletionActual
Oct 21, 2025
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 26, 2026
Interventions
Arm changed altSonflex1-2-3 Dose_A Group→altSonflex1-2-3 Low Dose Group; altSonflex1-2-3 Dose_B Group→altSonflex1-2-3 Medium Dose Group; altSonflex1-2-3 Dose_C Group→altSonflex1-2-3 High Dose Group
Oct 26, 2026
Primary outcomes
7 edited, 4 removed
What changed in the outcomes
  • EditedGeometric mean titersMean Concentrations (GMTsGMCs) of antiAnti-serotype-specific Specific Shigella lipopolysaccharidesLipopolysaccharide (LPS)/O-antigenAntigen (LPS/OAg) serumSerum Immunoglobulin G (IgG)Time frame: Day 1 (before administration of Dose 1) → At Day 1 (before administration of Dose 1)
  • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 169 (before administration of Dose 2) → At Day 29 (28 days after administration of Dose 1)
  • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 29 (28 days after administration of Dose 1) → At Day 169 (before administration of Dose 2)
  • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 197 (28 days after administration of Dose 2) → At Day 197 (28 days after administration of Dose 2)
  • EditedGeometric mean concentrations (GMCs)Number of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 1 (before administration of Dose 1) → At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
  • EditedGMCsNumber of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 169 (before administration of Dose 2) → At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
  • EditedGMCsNumber of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 29 (28 days after administration of Dose 1) → At Day 197 compared to pre-Dose 2 at Day 169
  • RemovedGMCs of anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 (28 days after administration of Dose 2)
  • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 29 compared with baseline (Day 1)
  • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 compared with baseline (Day 1)
  • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 compared with pre-Dose 2 (Day 169)
Oct 26, 2026
Documents
Secondary outcomes
10 edited, 2 added
What changed in the outcomes
  • EditedNumber of infants with solicited administration-site eventsParticipants With Solicited Administration Site EventsTime frame: During 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 7 days after each study intervention administration (study intervention administered at Day 1 and Day 169)
  • EditedNumber of infants with solicited systemic eventsParticipants With Solicited Systemic EventsTime frame: During 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
  • EditedNumber of infants with unsolicited adverse eventsParticipants With Unsolicited Adverse Events (AEs)Time frame: During 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
  • EditedNumber of infants with serious adverse eventsParticipants With Serious AEs (SAEs) during the entire study periodTime frame: From Day 1 to Day 197 → Day 1 to Day 197
  • EditedNumber of infants with deviations from laboratory reference values of hematologicalParticipants With Change From Baseline in Hematological, renalRenal, and hepatic panel test resultsHepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8Time frame: Day 8 compared with baseline (Day 1) → Day 8 compared to baseline (pre-Dose 1 at Day 1)
  • EditedNumber of infants with deviations from laboratory reference values of hematologicalParticipants With Change From Baseline in Hematological, renalRenal, and hepatic panel test results comparedHepatic Panel Test Results With Respect to pre-Dose 2 valuesLaboratory Reference Ranges at Day 176Time frame: Day 176 compared with pre-Dose 2 (Day 169) → Day 176 compared to pre-Dose 2 at Day 169
  • EditedAnti-measles IgG concentrations expressedConcentrations Expressed as GMCsTime frame: At Day 1 (before the first MR-VAC vaccination) and Day 197 (28 days after the second MR-VAC vaccination) → At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
  • EditedAnti-rubella IgG concentrations expressedConcentrations Expressed as GMCsTime frame: At Day 1 (before the first MR-VAC vaccination) and Day 197 (28 days after the second MR-VAC vaccination) → At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
  • EditedNumber of infants with Participants Achieving Anti-measles seroresponse >=IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and >=≥200 mIU/mLTime frame: At Day 197 (28 days after the second MR-VAC vaccination)
  • EditedNumber of infants with Participants Achieving Anti-rubella seroresponse >=IgG Concentrations of ≥4 IU/mL and >=≥10 IU/mLTime frame: Day 197 (28 days after the second MR-VAC vaccination) → At Day 197 (28 days after the second MR-VAC vaccination)
  • AddedThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade ValuesTime frame: Day 8 compared to baseline (before administration of Dose 1 at Day 1)
  • AddedThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade ValuesTime frame: Day 176 compared to pre-Dose 2 at Day 169
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Results posted
    Primary outcomes 7 edited, 4 removed
    What changed in the outcomes
    • EditedGeometric mean titersMean Concentrations (GMTsGMCs) of antiAnti-serotype-specific Specific Shigella lipopolysaccharidesLipopolysaccharide (LPS)/O-antigenAntigen (LPS/OAg) serumSerum Immunoglobulin G (IgG)Time frame: Day 1 (before administration of Dose 1) → At Day 1 (before administration of Dose 1)
    • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 169 (before administration of Dose 2) → At Day 29 (28 days after administration of Dose 1)
    • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 29 (28 days after administration of Dose 1) → At Day 169 (before administration of Dose 2)
    • EditedGMTsGMCs of antiAnti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 197 (28 days after administration of Dose 2) → At Day 197 (28 days after administration of Dose 2)
    • EditedGeometric mean concentrations (GMCs)Number of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 1 (before administration of Dose 1) → At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
    • EditedGMCsNumber of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 169 (before administration of Dose 2) → At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
    • EditedGMCsNumber of antiParticipants With at Least a 4-fold Increase in Anti-serotype-specific Specific Shigella LPS/OAg serumSerum IgGTime frame: Day 29 (28 days after administration of Dose 1) → At Day 197 compared to pre-Dose 2 at Day 169
    • RemovedGMCs of anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 (28 days after administration of Dose 2)
    • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 29 compared with baseline (Day 1)
    • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 compared with baseline (Day 1)
    • RemovedNumber of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgGTime frame: Day 197 compared with pre-Dose 2 (Day 169)
    Secondary outcomes 10 edited, 2 added
    What changed in the outcomes
    • EditedNumber of infants with solicited administration-site eventsParticipants With Solicited Administration Site EventsTime frame: During 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 7 days after each study intervention administration (study intervention administered at Day 1 and Day 169)
    • EditedNumber of infants with solicited systemic eventsParticipants With Solicited Systemic EventsTime frame: During 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 7 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
    • EditedNumber of infants with unsolicited adverse eventsParticipants With Unsolicited Adverse Events (AEs)Time frame: During 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169) → During the 28 days after each study intervention administration (study interventions administered at Day 1 and Day 169)
    • EditedNumber of infants with serious adverse eventsParticipants With Serious AEs (SAEs) during the entire study periodTime frame: From Day 1 to Day 197 → Day 1 to Day 197
    • EditedNumber of infants with deviations from laboratory reference values of hematologicalParticipants With Change From Baseline in Hematological, renalRenal, and hepatic panel test resultsHepatic Panel Test Results With Respect to Laboratory Reference Ranges at Day 8Time frame: Day 8 compared with baseline (Day 1) → Day 8 compared to baseline (pre-Dose 1 at Day 1)
    • EditedNumber of infants with deviations from laboratory reference values of hematologicalParticipants With Change From Baseline in Hematological, renalRenal, and hepatic panel test results comparedHepatic Panel Test Results With Respect to pre-Dose 2 valuesLaboratory Reference Ranges at Day 176Time frame: Day 176 compared with pre-Dose 2 (Day 169) → Day 176 compared to pre-Dose 2 at Day 169
    • EditedAnti-measles IgG concentrations expressedConcentrations Expressed as GMCsTime frame: At Day 1 (before the first MR-VAC vaccination) and Day 197 (28 days after the second MR-VAC vaccination) → At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
    • EditedAnti-rubella IgG concentrations expressedConcentrations Expressed as GMCsTime frame: At Day 1 (before the first MR-VAC vaccination) and Day 197 (28 days after the second MR-VAC vaccination) → At Day 1 (before the first MR-VAC) and at Day 197 (28 days after the second MR-VAC vaccination)
    • EditedNumber of infants with Participants Achieving Anti-measles seroresponse >=IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and >=≥200 mIU/mLTime frame: At Day 197 (28 days after the second MR-VAC vaccination)
    • EditedNumber of infants with Participants Achieving Anti-rubella seroresponse >=IgG Concentrations of ≥4 IU/mL and >=≥10 IU/mLTime frame: Day 197 (28 days after the second MR-VAC vaccination) → At Day 197 (28 days after the second MR-VAC vaccination)
    • AddedThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 8 Versus Baseline (Day 1) Grade ValuesTime frame: Day 8 compared to baseline (before administration of Dose 1 at Day 1)
    • AddedThe Number of Participants With Abnormal Hematological, Renal, and Hepatic Panel Test Results by Grade Values at Day 176 Versus Day 169 Grade ValuesTime frame: Day 176 compared to pre-Dose 2 at Day 169
    Interventions Arm changed altSonflex1-2-3 Dose_A Group→altSonflex1-2-3 Low Dose Group; altSonflex1-2-3 Dose_B Group→altSonflex1-2-3 Medium Dose Group; altSonflex1-2-3 Dose_C Group→altSonflex1-2-3 High Dose Group
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06663436
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Nov 13, 2024
Primary completion
Oct 21, 2025
Completion
Oct 21, 2025
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion